Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | Upcoming studies investigating linvoseltamab in myeloma

Faith Davies, MD, MRCP, MRCPath, FRCPath, NYU Langone Medical Center, New York, NY, briefly outlines the upcoming studies investigating linvoseltamab in patients with multiple myeloma (MM). The LINKER-MM1 trial (NCT03761108) assessed the agent in patients with triple-class refractory disease. New trials will move it into earlier lines of therapy and the newly diagnosed setting, both alone and in combination with transplant. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.